|

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

RECRUITINGN/ASponsored by University Hospital, Angers
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Angers
Started2021-10-28
Est. completion2023-04-28
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04942080

Summary

Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* adults (age ≥18 years),
* affiliated to the national social security system,
* with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,
* for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,
* who signed the consent to participate in the study,
* included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).

Exclusion Criteria:

* patient with another active hematological disease or cancer at the time of diagnosis,
* person subject to legal protection scheme or incapable of giving consent.

Conditions5

CancerEssential ThrombocythemiaMyeloproliferative NeoplasmPrimary Myelofibrosis, Fibrotic StagePrimary Myelofibrosis, Prefibrotic Stage

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.